Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Olopatadine + azelastine is a combination of two antihistamine drugs used primarily for the treatment of allergic conditions such as allergic rhinitis and conjunctivitis. Both agents are selective histamine H1 receptor antagonists that block the action of histamine released during allergic reactions. Olopatadine is commonly available as an ophthalmic solution (eye drops) for treating ocular symptoms like itching and redness due to allergies[1][5][6]. Azelastine is typically formulated as a nasal spray to relieve nasal symptoms such as congestion, sneezing, and runny nose associated with seasonal or perennial allergic rhinitis[3][4][7]. Both drugs have rapid onset of action and are well tolerated. They may be used individually or in combination with other therapies for enhanced symptom control in moderate-to-severe cases[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Olopatadine + azelastine.